Abstract. Schizophrenia is a chronic disease that requires relatively high treatment costs [1]. Several studies have found that atypical antipsychotics are more effective compared to typical antipsychotics. As a result, the duration of treatment and the patients’ length of hospital stay will be shorter which ultimately reduce the overall treatment costs. Therefore, it is necessary to conduct a cost-effectiveness analysis (CEA) of the two classes of antipsychotic drugs in the treatment of schizophrenia inpatients admitted to Jambi Province Hospital period 2013-2016. Method: This descriptive retrospective cohort study was undertaken to analyze cost-effectiveness of the antipsychotic drugs provided to patients with schizophrenia (n...
Background: Based on randomized clinical trials, consensus has been emerging that the first line of ...
Objective: To assess from a health sector perspective the incremental cost-effectiveness of eight dr...
Background: Based on randomized clinical trials, consensus has been emerging that the first line of ...
Copyright © 2008 ICMPEBACKGROUND: In two recent randomised clinical trials, a meta-analysis and in a...
Background: Schizophrenia patients mostly require life-long treatment. For such long-term treatments...
The aim: to provide a comprehensive pharmacoeconomic evaluation of the maintenance therapy with anti...
Background: Schizophrenia is the most common psychotic disorder and responsible for approximately ha...
Background: In two recent randomised clinical trials, a meta-analysis and in an effectiveness study ...
BACKGROUND: There are claims that the extra costs of atypical (second-generation) antipsychotic drug...
BACKGROUND: There are claims that the extra costs of atypical (second-generation) antipsychotic drug...
Background: There are claims that the extra costs of atypical (second-generation) antipsychotic drug...
Cost-effectiveness of treatment of schizophrenia with typical and atypical antipsychotics Introduct...
The aim: to provide a comprehensive pharmacoeconomic evaluation of the antipsychotic maintenance the...
Psychotic disorders create a burden on the government, family, and society because of decreasing pat...
Purpose: To evaluate the antipsychotic drugs most commonly prescribed for schizophrenia patients in ...
Background: Based on randomized clinical trials, consensus has been emerging that the first line of ...
Objective: To assess from a health sector perspective the incremental cost-effectiveness of eight dr...
Background: Based on randomized clinical trials, consensus has been emerging that the first line of ...
Copyright © 2008 ICMPEBACKGROUND: In two recent randomised clinical trials, a meta-analysis and in a...
Background: Schizophrenia patients mostly require life-long treatment. For such long-term treatments...
The aim: to provide a comprehensive pharmacoeconomic evaluation of the maintenance therapy with anti...
Background: Schizophrenia is the most common psychotic disorder and responsible for approximately ha...
Background: In two recent randomised clinical trials, a meta-analysis and in an effectiveness study ...
BACKGROUND: There are claims that the extra costs of atypical (second-generation) antipsychotic drug...
BACKGROUND: There are claims that the extra costs of atypical (second-generation) antipsychotic drug...
Background: There are claims that the extra costs of atypical (second-generation) antipsychotic drug...
Cost-effectiveness of treatment of schizophrenia with typical and atypical antipsychotics Introduct...
The aim: to provide a comprehensive pharmacoeconomic evaluation of the antipsychotic maintenance the...
Psychotic disorders create a burden on the government, family, and society because of decreasing pat...
Purpose: To evaluate the antipsychotic drugs most commonly prescribed for schizophrenia patients in ...
Background: Based on randomized clinical trials, consensus has been emerging that the first line of ...
Objective: To assess from a health sector perspective the incremental cost-effectiveness of eight dr...
Background: Based on randomized clinical trials, consensus has been emerging that the first line of ...